about
Temperament type specific metabolite profiles of the prefrontal cortex and serum in cattleGABAergic interneuron origin of schizophrenia pathophysiology.Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disordersNeurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodentsPlasticity of Hippocampal Excitatory-Inhibitory Balance: Missing the Synaptic Control in the Epileptic BrainBrain Structural Effects of Antidepressant Treatment in Major DepressionTLX: A master regulator for neural stem cell maintenance and neurogenesisMagnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literatureNeurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuseProgesterone receptors: form and function in brainHyperactivity, startle reactivity and cell-proliferation deficits are resistant to chronic lithium treatment in adult Nr2e1(frc/frc) miceAuditory steady state response in bipolar disorder: relation to clinical state, cognitive performance, medication status, and substance disordersMEG auditory evoked fields suggest altered structural/functional asymmetry in primary but not secondary auditory cortex in bipolar disorder.Reduced conditioned fear response in mice that lack Dlx1 and show subtype-specific loss of interneuronsQuantitative trait locus analysis identifies Gabra3 as a regulator of behavioral despair in mice.Evaluation of anticonvulsant, sedative, anxiolytic, and phytochemical profile of the methanol extract from the aerial parts of Swertia corymbosa (Griseb.) wight ex C.B. ClarkeMolecular imaging for depressive disorders.Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies.Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression.Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholismOxidative stress in early stage Bipolar Disorder and the association with response to lithiumAn exploration of the dynamic longitudinal relationship between mental health and alcohol consumption: a prospective cohort study.Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression.Biological substrates underpinning diagnosis of major depression.Cortical Plasticity in Depression.Altered miRNA expression network in locus coeruleus of depressed suicide subjectsExcitability of the motor cortex in de novo patients with celiac disease.Leptin potentiates GABAergic synaptic transmission in the developing rodent hippocampus.Association of the GABRD gene and childhood-onset mood disordersDecreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder.Why are cortical GABA neurons relevant to internal focus in depression? A cross-level model linking cellular, biochemical and neural network findings.Adult depression-like behavior, amygdala and olfactory cortex functions are restored by odor previously paired with shock during infant's sensitive period attachment learning.Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior.Perisomatic GABAergic innervation in prefrontal cortex is regulated by ankyrin interaction with the L1 cell adhesion molecule.Potential mechanisms of action of lithium in bipolar disorder. Current understanding.Antidepressant-like properties of α2-containing GABA(A) receptors.Stress impairs GABAergic network function in the hippocampus by activating nongenomic glucocorticoid receptors and affecting the integrity of the parvalbumin-expressing neuronal network.Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system.Homology modeling of human γ-butyric acid transporters and the binding of pro-drugs 5-aminolevulinic acid and methyl aminolevulinic acid used in photodynamic therapy.Neurosteroids are endogenous neuroprotectants in an ex vivo glaucoma model.
P2860
Q21090552-5E594F59-2BDB-44A0-9240-199CAD9869BBQ24597790-16636AEC-01C4-4E4A-A29A-828D6F797079Q24632936-6E276498-DEBA-4F12-8279-9B13F729AFA0Q24656267-123D34EC-163E-4095-A6FF-453451FC8136Q26752412-571F8959-A772-46BD-AB70-9D2887E3F834Q26786239-9E9A1FBC-3945-41FB-9AC8-5E0979FABF47Q26999359-8E0AF62A-B990-4A44-A508-E56ED67E6562Q27026039-E04E2E4B-E0CA-4BDE-98BD-621ADD967D17Q28076105-1156A11E-5F2D-472B-94D4-48822F1E78FDQ28274391-D6E425A6-415F-4ABB-B368-1EBD1905F268Q30469863-09B8E383-A52C-40BB-A017-7C3746E5E382Q30472479-06BA8D7C-9BDA-4A1B-BBF0-88FD94F79F10Q30480452-22280C6C-3C88-496B-9E50-1BD17C18AE39Q30486124-BDBB081A-CC04-4CB3-9EEF-75DEB76E1849Q30495091-BC923F56-C5B5-4C6A-B99F-0EFCFDA8C5FFQ30578177-55B9742A-B238-4447-9C34-9EBE0F12A3A5Q30821361-EC26D998-5A1F-4465-B547-D39EEC629425Q31090438-F55132E3-B603-4E50-90AC-BAF5DE1B41FDQ33492323-D89EDA2F-8DBD-41B1-845F-131FF4DE86A1Q33548809-390A2060-3215-4AF9-9976-DC38DDE668A1Q33738259-31D5E6E1-5BE8-416E-A096-983887A71132Q33740064-2538E627-687B-445C-B232-227EA89AE1F3Q33802572-7903300E-0159-48C5-98DE-0AD0CFF52DF4Q33820463-95FDB8B2-4E39-42DD-9111-44E284290A44Q33824966-F3291057-DEDE-4E66-81F8-8C1F3A8D8D4AQ33854240-E8AEBAF6-1786-43EB-ABA6-923E2594430CQ33951544-2274F861-5060-4598-9D06-A05A025BDFF2Q34048680-0D8D192C-DEA9-4C00-9F5C-F8E9BD8999B7Q34111492-DE7D34D8-5140-4F45-BF25-77D431F2E8EAQ34181837-39FAA945-EECD-4D47-89EC-3A2635A61CDDQ34216839-A18ADFC8-4E02-45DF-AD58-E66E50F617B7Q34244698-0935E969-5CFC-4CE4-9B4A-B79A1A9FB7FBQ34308231-DE4D961F-3ECF-4C9E-A89E-EAA03EED435AQ34308394-4F6655FF-4E54-4FA4-8B5B-EE9DDFB9524CQ34325612-881FC53C-78AD-4AB4-842B-603C9C45C8F0Q34504773-F9714B8D-332A-4F34-B32C-F255258C8A51Q34661056-5DD5E0BE-087E-4E43-B2D2-E24112D1A085Q34722740-EA46362C-5126-4689-85D9-A8A10C106D92Q34769682-E9C5CB5F-2AE7-4C03-AC1F-9BF0FFC0023BQ34789708-45E0D3DE-FF68-46F1-A35E-EBC860C86891
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
GABAergic dysfunction in mood disorders.
@ast
GABAergic dysfunction in mood disorders.
@en
type
label
GABAergic dysfunction in mood disorders.
@ast
GABAergic dysfunction in mood disorders.
@en
prefLabel
GABAergic dysfunction in mood disorders.
@ast
GABAergic dysfunction in mood disorders.
@en
P2093
P2860
P356
P1433
P1476
GABAergic dysfunction in mood disorders
@en
P2093
P2860
P2888
P304
721-37, 715
P356
10.1038/SJ.MP.4001362
P407
P577
2003-08-01T00:00:00Z